A common medication used to manage and treat HIV is becoming increasingly resistant, according to a report from the World Health Organization. Dolutegravir is an antiretroviral medication that is ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...
GSK's antiretroviral HIV medicine Tivicay (dolutegravir) has been recommended by the World Health Organization (WHO) since 2018 as a preferred treatment for the virus. Now, the same agency is flagging ...
Human immunodeficiency virus (HIV) is a virus that attacks the immune system and weakens the body’s ability to fight off infection. If left untreated, the disease can progress to acquired ...
HIV virus is one of the most pressing health concerns facing the modern world. Since the first reported case of HIV/AIDS in 1981, over 25 million people have died. Out of the millions of people ...
Just as life is ever-evolving, so is the HIV treatment landscape. Thanks to decades of therapeutic improvements, people with HIV are living longer, healthier lives, but additional treatment needs may ...
Salk Institute researchers, in collaboration with National Institutes of Health (NIH) scientists, have discovered the molecular mechanisms by which human immunodeficiency virus (HIV) becomes resistant ...
LA JOLLA (July 21, 2023)—Salk Institute researchers, in collaboration with the National Institutes of Health, have discovered the molecular mechanisms by which the human immunodeficiency virus (HIV) ...
Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback